Detalles de la búsqueda
1.
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
J Clin Oncol;
42(9): 994-1000, 2024 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38252901
2.
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Mol Cancer;
22(1): 175, 2023 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37915024
3.
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
Mol Cancer Ther;
22(12): 1365-1375, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37788341
4.
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.
Ther Adv Med Oncol;
15: 17588359231178125, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37275963
5.
Integrative transcriptomics and cell systems analyses reveal protective pathways controlled by Igfbp-3 in anthracycline-induced cardiotoxicity.
FASEB J;
37(6): e22977, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37219486
6.
Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
Clin Cancer Res;
29(11): 2131-2143, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36884217
7.
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.
J Clin Oncol;
41(8): 1501-1510, 2023 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36881998
8.
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
J Clin Oncol;
41(9): 1638-1645, 2023 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36921335
9.
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
Breast Cancer Res;
25(1): 2, 2023 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36631725
10.
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
Clin Cancer Res;
29(1): 40-49, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36136304
11.
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib.
Oncologist;
27(10): 811-821, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35917168
12.
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
Clin Cancer Res;
28(16): 3433-3442, 2022 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35552673
13.
Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.
Mol Cancer Ther;
21(5): 751-761, 2022 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35417017
14.
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer.
Clin Cancer Res;
28(9): 1854-1862, 2022 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35110416
15.
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.
Nat Cancer;
2(4): 400-413, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34966897
16.
A careful reassessment of anthracycline use in curable breast cancer.
NPJ Breast Cancer;
7(1): 134, 2021 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34625570
17.
Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Clin Cancer Res;
27(17): 4939, 2021 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34470810
18.
Cycling cancer persister cells arise from lineages with distinct programs.
Nature;
596(7873): 576-582, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34381210
19.
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
PLoS One;
16(5): e0251163, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33951110
20.
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Clin Cancer Res;
27(17): 4870-4882, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33536276